Charles River has acquired the capture compound mass spectrometry (CCMS) target identification platform from caprotec bioanalytics, GmbH, as of July 2017.
The addition of the technology to our Discovery business offers you a significant step forward in the discovery and early development process by providing a better understanding of the on-target based efficacy and off-target based side effect liabilities, which enable better informed decision making when considering your target selection strategy.
This cutting edge LC-MS platform identifies and validates targets from phenotypic screens and can also identify molecular targets of key compounds from a wide range of biological matrices. Learn more about the CCMS technology and its applications:
Chemistry decision making
Supporting projects across discovery and development